Craig Skaling
@Tcg Crossover Management, Llc
Latest period2024 - Q3ReportedManaged Assets$1.18BTotal holdings36
Assets growth rate23.02%Assets growth rate (2-Q avg)-0.56%Continuous growth in asset value1 quarters
Portfolio positions
This chart displays the top 10 holdings in Tcg Crossover Management, Llc's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 36 positions.
Assets under management
The assets under management (AUM) of Tcg Crossover Management, Llc over the past 10 years (40 quarters) show continuous growth in total asset value over the last 1 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 1.18B in assets, with a quarterly growth rate of 23.02% and a 2-quarter average growth rate of -0.56%. The portfolio is managed by Craig Skaling, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
CGONCg Oncology, Inc.
| 11.74% | $138.477M 3.67M shares@ $37.73 avg price | |
DYNDyne Therapeutics, Inc
| 8.07% | $95.193M 2.65M shares@ $35.92 avg price | |
COGTCogent Biosciences Inc
| 6.38% | $75.215M 6.964M shares@ $10.8 avg price | |
ABVXAbivax Sa
| 5.92% | $69.772M 6.057M shares@ $11.53 avg price | |
EWTXEdgewise Therapeutics, Inc.
| 4.78% | $56.396M 2.113M shares@ $26.7 avg price | Decreased -7.02% |
SLNSilence Therapeutics Plc
| 4.68% | $55.15M 3.034M shares@ $18.19 avg price | Decreased -7.94% |
SVRASavara Inc.
| 4.45% | $52.416M 12.362M shares@ $4.24 avg price | |
KROSKeros Therapeutics, Inc.
| 4.33% | $51.064M 879,344 shares@ $58.07 avg price | |
XNCRXencor Inc
| 4.14% | $48.81M 2.427M shares@ $20.11 avg price | New Position |
TYRATyra Biosciences Inc
| 3.97% | $46.764M 1.989M shares@ $23.52 avg price |